drugset / Trial / NCT04729517
Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients
Phase 3
Completed
210 enrolled
Abdi Ibrahim Ilac San. ve Tic A.S.
Ankara City Hospital Bilkent · collabAntalya Training and Research Hospital · collabDiskapi Yildirim Beyazit Education and Research Hospital · collabDokuz Eylul University · collabKahramanmaras Sutcu Imam University · collabKaradeniz Technical University · collabKartal Dr. Lütfi Kirdar City Hospital · collabUludag University · collabUmraniye Education and Research Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, national, randomized, multicenter, parallel group, Phase III study that evaluates the effects of AI201901 in Allergic Rhinitis patients, where they will spray twice a day against azelastine into both nostrils during a 28-day follow-up period.
Timeline
- Start
- 2021-04-20
- Primary completion
- 2023-03-03
- Completion
- 2023-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AI201901 | Unknown | — | Inhaled |
| Comparator | Azelastine | Small molecule | — | Inhaled |